8-K/A: Jupiter Neurosciences Amends Equity Purchase Deal, Convertible Note Terms

Jupiter Neurosciences, Inc. filed an amendment to its Standby Equity Purchase Agreement and Convertible Promissory Note with YA II PN, Ltd., adjusting share counts and conversion caps.

Summary

• Jupiter Neurosciences, Inc. (the Company) filed an amendment to its Standby Equity Purchase Agreement (SEPA) and an Amended and Restated Convertible Promissory Note (A&R Note) with YA II PN, Ltd. (Yorkville) on November 19, 2025.
• The amendment updated the number of outstanding common shares as of October 24, 2025, from 34,833,083 to 34,294,446.
• It also revised the Exchange Cap, limiting shares issuable under the SEPA and Convertible Notes, from 7,180,504 to 6,855,459 shares (19.99% of pre-SEPA outstanding shares).
• The SEPA allows the Company to sell up to $20.0 million of its common stock to Yorkville over 24 months.
• The Company received an initial $3,720,000 Pre-Paid Advance on October 27, 2025, in exchange for a $4.0 million principal Convertible Note, issued with a 7.0% original issue discount (OID).
• A second $1,860,000 Pre-Paid Advance for a $2.0 million principal Convertible Note is contingent on SEC registration statement effectiveness and stockholder approval to exceed the Exchange Cap.
• Convertible Notes carry an 8% annual interest rate, increasing to 18% upon an Event of Default, and mature on October 24, 2026.
• Monthly repayments commence 75 days after October 24, 2025, including 1/10th of outstanding principal, a 5% Payment Premium (waived if repaid via Advance Repayment), and accrued interest.
• The Company will seek stockholder approval at its December 19, 2025, annual meeting to issue shares exceeding the Exchange Cap, which is necessary to fully utilize the $20.0 million SEPA commitment.
• Proceeds from SEPA advances, after note repayment, are designated for the Phase 2 JOTROL trial, Nugevia.com marketing, and general corporate purposes.
• The Company paid a $25,000 structuring fee and issued 131,909 Commitment Shares (valued at $200,000) to Yorkville.
• Revere Securities LLC will receive an 8.0% finder's fee on Pre-Paid Advances and $18,000 per month for 12 months, payable upon raising $5.0 million or more in additional financing.

Sentiment

Score: 6

Explanation: The filing confirms a significant financing arrangement, providing crucial capital for key initiatives. However, the terms involve substantial potential dilution, high interest rates on notes, and the need for shareholder approval for full utilization, which introduces uncertainty and cost. The amendment itself is largely administrative, clarifying previously announced terms.

Positives

• Secured a commitment for up to $20.0 million in equity financing from Yorkville, providing a flexible capital source.
• Received an initial $3,720,000 Pre-Paid Advance, offering immediate capital for operations and strategic initiatives.
• Future proceeds from SEPA advances are earmarked for critical projects, including the Phase 2 trial of JOTROL for Parkinson's Disease and accelerating Nugevia.com marketing and sales.
• Yorkville is prohibited from engaging in short selling or hedging transactions that establish a net short position in the Company's common stock, potentially reducing downward pressure on the stock price from the investor.

Negatives

• The Convertible Notes carry an 8% annual interest rate, which increases significantly to 18% upon an Event of Default, raising the cost of capital.
• A 7.0% Original Issue Discount (OID) on the Convertible Notes reduces the net cash proceeds received by the Company from the principal amount.
• A 5% Payment Premium is applied to monthly principal repayments if not repaid through an Advance Repayment, increasing repayment costs.
• The Exchange Cap of 6,855,459 shares (19.99% of pre-SEPA outstanding shares) limits the Company's ability to fully utilize the $20.0 million SEPA commitment without obtaining specific stockholder approval.
• Restrictions are placed on the Company's ability to enter into certain Variable Rate Transactions and repay related party debt until the Convertible Notes are fully repaid, potentially limiting future financing flexibility.
• Finder's fees, including 8.0% of Pre-Paid Advances and $18,000 per month for 12 months, reduce the net capital available from the financing.

Risks

• Dilution Risk: Conversion of the Convertible Notes and sales of common stock under the SEPA, especially if the stock price declines, could lead to significant dilution for existing shareholders.
• Stockholder Approval Risk: Failure to obtain the required stockholder approval at the December 19, 2025, annual meeting to exceed the Exchange Cap will severely limit the Company's access to the full $20.0 million SEPA commitment and the second Pre-Paid Advance.
• Market Price Volatility Risk: The Variable Price conversion mechanism, triggered by an Event of Default, links the conversion price to the lowest daily VWAP, potentially leading to more shares being issued at lower prices.
• Event of Default Risk: Various conditions, including failure to make timely payments, bankruptcy, or significant judgments, could trigger an Event of Default, resulting in an increased interest rate (18%) and immediate acceleration of debt repayment.
• Liquidity Risk: The Company's ability to meet its repayment obligations and fund operations is dependent on its ability to sell shares under the SEPA or secure alternative financing.
• Regulatory Compliance Risk: Failure to timely file periodic reports with the SEC or comply with Nasdaq listing rules could constitute an Event of Default.

Future Outlook

The Company intends to use proceeds from SEPA advances, after the full repayment of the Convertible Notes, to support its Phase 2 clinical trial for JOTROL in Parkinson's Disease and to accelerate direct-to-consumer marketing and sales growth for its Nugevia.com nutritional product line. The Company is actively seeking stockholder approval at its upcoming December 19, 2025, annual meeting to enable the issuance of shares beyond the current Exchange Cap, which is crucial for fully accessing the $20.0 million aggregate purchase commitment from Yorkville.

Management Comments

• The Company will seek the requisite stockholder approval in accordance with Rule 5635(d) of the Nasdaq Listing Rules (in addition to the requisite stockholder approval under Nasdaq Listing Rule 5635(b)) to issue and sell shares of Common Stock in excess of the 6,855,459 share Exchange Cap referred to above to Yorkville under the SEPA and upon conversion of the Convertible Notes.
• If such requisite stockholder approval is obtained at the 2025 Annual Stockholders Meeting, the Company would be able to issue and sell to Yorkville in Advances under the SEPA as many shares of Common Stock as will be necessary for the Company to obtain the entire $20.0 million aggregate purchase commitment.
• The Company expects that any proceeds received from such sales to Yorkville in one or more Advances under the SEPA will be used primarily to support its Phase 2 trial of its lead asset, JOTROL, for the treatment of Parkinson's Disease and to accelerate direct-to-consumer marketing and sales growth of its recently launched nutritional product line Nugevia.com, as well as for working capital and other general corporate purposes.

Industry Context

This financing arrangement is typical for a growth-stage biotechnology company like Jupiter Neurosciences, which requires substantial capital for clinical trials (JOTROL for Parkinson's Disease) and commercialization efforts (Nugevia.com). Standby Equity Purchase Agreements with convertible notes provide flexible access to capital, often used by companies that may not have consistent access to traditional debt markets or larger equity raises. The need for shareholder approval to exceed the 19.99% Nasdaq cap is a standard regulatory requirement for such dilutive transactions, reflecting a balance between capital access and shareholder protection.

Comparison to Industry Standards

• The 19.99% Exchange Cap is a standard Nasdaq listing rule (Rule 5635(d)) that many small-cap and growth companies, particularly in biotech, encounter when structuring equity financing to prevent excessive dilution without explicit shareholder consent. This is a common hurdle for companies like Jupiter Neurosciences seeking to raise capital through equity lines.
• The 8% annual interest rate on the convertible notes is within the typical range for non-investment grade or growth-stage companies, reflecting the inherent risk profile. However, the 18% default interest rate is on the higher end, indicating a significant penalty for non-compliance, comparable to distressed debt terms.
• The 7% Original Issue Discount (OID) and 5% payment/redemption premiums are common features in structured financings for smaller companies, effectively increasing the true cost of capital beyond the stated interest rate, similar to arrangements seen with other emerging biotech firms.
• The allocation of funds towards a Phase 2 clinical trial (JOTROL) and direct-to-consumer marketing (Nugevia.com) aligns with the strategic priorities of many companies in the pharmaceutical and consumer health sectors, respectively, as they progress through development and commercialization stages.

Corporate Governance

Related Party Transactions

• The Company is permitted to pay one-half of 2022-2024 outstanding bonuses to its executives after the disbursement of the first Pre-Paid Advance.
• Another one-half of the 2022-2024 outstanding bonuses to executives is permitted after the disbursement of the second Pre-Paid Advance.
• The Company is prohibited from repaying any other related party debt, including outstanding and accrued salaries, until the Convertible Notes are fully repaid.

Stakeholder Impact

• Shareholders: Face potential for significant dilution from the conversion of notes and sales of common stock under the SEPA, particularly if the stock price declines. The upcoming shareholder vote on the Exchange Cap provides a direct influence on the extent of future dilution.
• Employees/Executives: Certain outstanding bonuses are permitted to be paid, but other related party debt repayments are restricted until the Convertible Notes are fully repaid.
• Creditors (Yorkville): Benefits from an 8% interest rate (18% on default) and flexible conversion rights, allowing them to convert to equity or demand cash repayment. Protected by various Event of Default clauses and restrictions on the Company's other financings.

Next Steps

• The Company is obligated to file a registration statement for the resale of shares issuable under the SEPA within 30 calendar days after October 24, 2025.
• Hold the 2025 Annual Stockholders Meeting on December 19, 2025, to seek stockholder approval for issuing shares in excess of the Exchange Cap.
• Disbursement of the second Pre-Paid Advance and issuance of the second Convertible Note will occur after the initial Registration Statement becomes effective and stockholder approval for exceeding the Exchange Cap is obtained.
• Monthly repayments of the Convertible Notes will commence on the 75th calendar day after October 24, 2025.
• Utilize future SEPA proceeds (after note repayment) to support the Phase 2 trial for JOTROL and accelerate marketing and sales for Nugevia.com.

Key Dates

Recommendation

The financing provides crucial capital for Jupiter Neurosciences' strategic initiatives, which is a positive. However, the terms involve substantial potential dilution for existing shareholders, high financing costs (OID, premiums, default interest), and the uncertainty of obtaining shareholder approval for full utilization of the SEPA. Investors should hold to monitor the outcome of the shareholder vote and the company's execution on its strategic plans, weighing the capital infusion against the dilution risk.

Keywords

Jupiter Neurosciences, JUNS, SEC filing, 8-K/A, convertible promissory note, standby equity purchase agreement, SEPA, YA II PN Ltd, Yorkville, equity financing, dilution, capital raise, Nasdaq, JOTROL, Nugevia